You are here

  • Home
  • Archive
  • Volume 5, Issue 4
  • Losartan reduced stroke and new onset diabetes more than atenolol in essential hypertension with signs of left ventricular hypertrophy

Article Text

Article menu
Download PDFPDF
Treatment
Losartan reduced stroke and new onset diabetes more than atenolol in essential hypertension with signs of left ventricular hypertrophy

https://doi.org/10.1136/ebn.5.4.112

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Dahlöf B, Devereux RB, Kjeldsen SE, et al.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lancet2002 Mar 23;359:995–1003OpenUrlCrossRefPubMedWeb of Science

    QUESTION: In patients with essential hypertension and signs of left ventricular hypertrophy (LVH), is losartan based treatment more effective than atenolol based treatment?

    Design

    Randomised (unclear allocation concealment), blinded (patients and monitoring committee), controlled trial with ≥4 years of follow up.

    Setting

    Multicentre trial in Europe and the US.

    Patients

    9222 patients 55–80 years of age (mean age 67 y, 54% women) with hypertension (sitting blood pressure [BP] of 160–200 mm Hg systolic, 95–115 mm Hg diastolic, or both after 1–2 wks of placebo) and electrocardiographic signs of LVH. Exclusion criteria included secondary hypertension; myocardial infarction (MI) or stroke within the …

    View Full Text

    Footnotes

    • Source of funding: Merck.

    • For correspondence: Professor B Dahlöf, Sahlgrenska University Hospital/Östra, Gothenburg, Sweden. bdahlof{at}scandinaviancri.se

    • A modified version of this abstract appears in ACP Journal Club.